Beyond Borders: global biotech report 2013
We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more in our 2013 industry report
Life Sciences deal sentiment scorecard
What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.
mHealth: Mobile tech poised to enable new era in health care
Gain new insights on impact of technology innovation on health care and its stakeholders-patients, physicians, providers and payers.
SEC comments and trends, January 2013
As you head into the year-end reporting season, read our insights based on review of SEC staff comments on recent public life sciences company filings.
The shifting pharmaceutical industry landscape
Discover the accounting and regulatory trends affecting reporting for 2012 and planning for 2013.
Pharma's $100 billion growth gap
As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.
Implementing the medical device excise tax
A 2.3% US excise tax on the sale, lease, rental or use of certain med devices goes into effect 1 January 2013. Is your company ready?
Cash on prescription 2012
In 2011, Big Pharma reported weaker working capital performance compared with 2010. Pressured to improve shareholder value, what measures can companies undertake to restore performance?

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

Biotechnology

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

Take a closer look:

Pharmaceutical

Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

Take a closer look:

Medical technology

Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

Take a closer look: